SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$5.28
-$0.07(-2.14%)
At close: 4:00 PM EST
$5.28
-$0.07(-2.14%)
Day’s Range― - ―
52-Week Range$2.58 - $5.70
Previous CloseN/A
Volume4.05K
Average Volume (3M)100.95K
Market Cap
$363.36M
Enterprise Value$371.14M
Total Cash (Recent Filing)$70.29M
Total Debt (Recent Filing)$63.02M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 12, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding71,668,700
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue4.80
Enterprise Value/Gross Profit7.13
Enterprise Value/Ebitda-5.67
Forecast
1Y Price Target
$7.50Price Target Upside42.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$93.25M
Bulls Say, Bears Say
Bulls Say
Backlog And ImplementationsA substantial backlog of signed customers awaiting implementation could drive a meaningful step-up in revenue and margins as onboarding completes and new applications go live.
Rising Contract Values And Customer AdditionsRising average contract values combined with record new customer signings are expected to lift average selling prices and revenue per customer.
U.S. Expansion And Biopharma PartnershipsStrengthening U.S. commercial traction and partnerships with major pharmaceutical companies are expanding market access and supporting larger, higher-value deals.
Bears Say
Foreign Exchange VolatilityForeign exchange tailwinds that boosted reported revenue may reverse, exposing underlying results to currency-driven volatility and potential headwinds.
Regional Execution Risk From Global FootprintA broad global footprint increases exposure to uneven regional performance and operational execution issues that can dampen reported growth in some markets.
Revenue Lumpiness From Contract TimingLarge biopharma contracts and staggered customer implementations create lumpy revenue recognition and short-term uncertainty in quarterly results.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.58 and its highest was $5.70 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $363.36M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is May 12, 2026 which is in 23 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Mar 03, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.238 by -$0.042.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.23.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 71,668,700 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.238. Following the earnings report the stock price went down -11.255%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (42.05% Upside)
$7.50 (42.05% Upside)
Hedge Fund Trend
Increased
By 430.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.40%
12-Months-Change
Fundamentals
Return on Equity
-116.98%
Trailing 12-Months
Asset Growth
4.50%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
SOPH Company Deck
SOPH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful commercial momentum: accelerating revenue growth, record new customer signings (124), strong implementation throughput (102), scalable platform improvements (1 PB processed, new DDM performance), improved adjusted gross margin (+140 bps to 74.2%), and strong retention/expansion metrics (NDR 115%, churn <1%). Management provided constructive 2026 guidance (20%–22% revenue growth) and a path toward improved adjusted EBITDA (guidance implying significant reduction in adjusted EBITDA loss). Offsetting these positives are persistent operating losses, higher reported operating expenses driven by FX movements (Swiss franc appreciation), litigation costs (~$1.8M), and the inherently long and lumpy nature of biopharma revenues and large customer implementations. Overall, the fundamentals and forward guidance show more strengths than weaknesses, but execution risks (implementation timing, FX, legal) remain and will be important to monitor.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$7.50
▲(42.05% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
8.98% Insiders
1.54% Mutual Funds
3.60% Other Institutional Investors
85.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---